Radiohalogenated agents for in situ immune modulated cancer vaccination

A method of treating a metastatic cancer in a subject, wherein the metastatic cancer comprises a primary malignant solid tumor and one or more metastatic tumors capable of causing concomitant immune tolerance, the method comprising the steps of:

• (a) administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue and comprises a metaiodobenzylguanidine (MIBG), wherein the iodine atom in the MIBG is a radioactive iodine isotope, or a phospholipid compound having the formula:
• or a salt thereof, wherein:
• R1 comprises a radioactive halogen isotope;
• a is 0 or 1;
• n is an integer from 12 to 30;
• m is 0 or 1;
• Y is selected from the group consisting of —H, —OH, —COOH, —COOX, —OX, and —OCOX, wherein X is an alkyl or an arylalkyl;
• and
• R2 is selected from the group consisting of —N+H3, —N+H2Z, —N+HZ2, and —N+Z3, wherein each Z is independently an alkyl or an aryl;
• and
• (b) performing in situ tumor vaccination in the subject at the primary malignant solid tumor using one or more treatments capable of stimulating specific immune cells within the tumor microenvironment, wherein the one or more treatments capable of stimulating specific immune cells within the tumor microenvironment comprise contacting the primary malignant solid tumor with a composition comprising one or more agents capable of stimulating specific immune cells within the tumor microenvironment;
• whereby the concomitant immune tolerance caused by the metastatic tumors is prevented and the metastatic cancer is treated in the subject.